{"id":875,"date":"2020-08-26T09:32:18","date_gmt":"2020-08-26T09:32:18","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/in-multiple-myeloma-different-types-of-blood-biopsies-match-up-well-with-bone-marrow-tests\/"},"modified":"2021-01-08T11:08:43","modified_gmt":"2021-01-08T11:08:43","slug":"in-multiple-myeloma-different-types-of-blood-biopsies-match-up-well-with-bone-marrow-tests","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/in-multiple-myeloma-different-types-of-blood-biopsies-match-up-well-with-bone-marrow-tests\/","title":{"rendered":"In multiple myeloma, different types of blood biopsies match up well with bone marrow tests"},"content":{"rendered":"<p><span lang=\"EN-GB\">Bone marrow biopsies are the gold standard for diagnosing and monitoring the progression of multiple myeloma, but these procedures are far too invasive to perform at every patient visit. Scientists from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, however, have shown that two ways to measure multiple myeloma DNA in blood samples provide highly detailed sets of genetic information that agree well not just with each other but with results from bone marrow tests.<\/span><br \/>\n<span lang=\"EN-GB\">\u201cUntil now, we haven\u2019t had a good way to measure how multiple myeloma cell populations evolve from precursor stages to diagnosed disease, and then respond to treatments, says Irene Ghobrial, MD, a Dana-Farber medical oncologist. \u201cThis is where blood biopsies can make a huge difference\u2014extending our understanding of multiple myeloma, and really giving us a timeline of how the disease progresses and responds to therapy.\u201d<\/span><br \/>\n<span lang=\"EN-GB\">The collaborative research examined blood biopsies that gathered multiple myeloma tumour DNA from two sources. One is circulating free DNA (cfDNA), scraps of DNA released into the bloodstream by dying cells. The other is circulating tumour cells (CTCs)\u2014myeloma cells themselves.<\/span><br \/>\n<span lang=\"EN-GB\">\u201cOur discovery that cfDNA and CTC analyses agree with each other at the comprehensive level is an important finding, because this means that routine genetic profiling of patient tumours from blood would be feasible,\u201d says Ghobrial, co-senior author on a paper reporting the work in Nature Communications.<\/span><br \/>\n<span lang=\"EN-GB\">The blood biopsy analyses followed a two-step sequencing approach, says Viktor Adalsteinsson, PhD, group leader of the Blood Biopsy Team at the Broad Institute and co-senior author on the paper. The first step, developed by his team and called \u201cultra-low pass\u201d whole genome sequencing, was a cost-effective method to identify blood samples with tumour DNA fraction of at least 5-10%, allowing more comprehensive genetic analysis. In the second step, the researchers performed whole exome sequencing (analysing the protein-coding regions of the genome) on those samples.<\/span><br \/>\n<span lang=\"EN-GB\">The investigators examined cfDNA from 107 patients and CTCs from 56 patients. The scientists then matched up cfDNA with bone marrow data from nine patients, and compared all three forms of biopsy in four additional patients. Overall, the gene profiles overlapped closely\u2014demonstrating about 99% agreement between liquid and bone marrow biopsies for tumour gene mutations, for instance.<\/span><br \/>\n<span lang=\"EN-GB\">Such high levels of agreement suggest that the two forms of liquid biopsy might be used interchangeably to track patients with multiple myeloma, the researchers say, and employing both techniques might further increase the chances of understanding the disease in each patient.<\/span><\/p>\n<p><span lang=\"EN-GB\">Dana-Farber Institute<link http:\/\/www.dana-farber.org\/newsroom\/news-releases\/2018\/in-multiple-myeloma--different-types-of-blood-biopsies-match-up-well-with-bone-marrow-tests\/ _blank external-link-new-window \"Opens external link in new window\">www.dana-farber.org\/newsroom\/news-releases\/2018\/in-multiple-myeloma&#8211;different-types-of-blood-biopsies-match-up-well-with-bone-marrow-tests\/<\/link><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bone marrow biopsies are the gold standard for diagnosing and monitoring the progression of multiple myeloma, but these procedures are far too invasive to perform at every patient visit. Scientists from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, however, have shown that two ways to measure multiple myeloma DNA in [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/875"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=875"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/875\/revisions"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}